Context Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025. At the meeting, stockholders ratified the appointment of CohnReznick LLP as the independent registered public accounting firm for the year ending December 31, 2025. Additionally, stockholders approved an amendment to the Amended and Restated Certificate of Incorporation to effect a reverse stock split of the outstanding common stock at a ratio ranging from 1-for-5 to 1-for-50, as determined by the Board of Directors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.